Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Strive Nasdaq listing and $450 million at-the-market offering
We advised Strive on its Nasdaq listing and offering
Enovix $360 million convertible senior notes and capped call transactions
The 4.75% convertible notes are due 2030
Elevance Health $3 billion senior notes offering
The investment-grade notes are due 2028, 2032, 2036 and 2055
Home Depot $2 billion notes offering
The investment-grade notes are due 2028, 2030 and 2035
Oesterreichische Kontrollbank $1.5 billion notes offering
The 3.75% notes are due 2030
Planet Labs PBC $460 million convertible senior notes offering
The 0.50% convertible senior notes are due 2030
Gemini Space Station $450 million IPO
The shares are listed on the Nasdaq Global Select Market
Alnylam Pharmaceuticals $661.25 million convertible senior notes offering
The 0% convertible notes are due 2028
Legence $728 million IPO
The shares are listed on the Nasdaq Global Select Market